Funding for this research was provided by:
Received: 4 April 2023
Accepted: 26 June 2023
First Online: 3 August 2023
: Respondents were required to provide written informed consent online. Participants were informed that their personal de-identified study-related data would be used in accordance with local privacy and data protection laws. The study protocol was approved by Advarra Institutional Review Board in the United States.
: Not applicable.
: RBL has received research support from the National Institutes of Health, the FDA, and the National Headache Foundation. He serves as consultant, advisory board member, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Dr. Reddy’s Laboratories (Promius), electroCore, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, Vector, and Vedanta Research. He receives royalties from <i>Wolff’s Headache</i>, 8th edition (Oxford University Press, 2009), and Informa. He holds stock in Biohaven and Manistee.EE, NDA, and DS were employees of OPEN Health Group at the time of study conduct.LD serves as a consultant, advisory board member, or has received honoraria from AbbVie, Amgen, Eli Lilly, Novartis, and Teva.AMA, JC-DL, and KS are employees of AbbVie and may hold AbbVie stock.SH serves as a consultant, advisory board member, or has received honoraria from AbbVie, Amgen, Biohaven, Currax, Eli Lilly, Impel, Lundbeck, Novartis, Teva, Theranica, and Upsher-Smith.